Therigy Debuts RSV Solution for TherigySTM

Maitland, FL (November 10, 2014) — Therigy today announced the release of a new module, Respiratory Syncytial Virus (RSV), within its specialty therapy management application TherigySTM. Currently, Synagis® is the only FDA-approved drug commercially available in the United States for …

Therigy Launches New Website

Therigy, LLC, is pleased to announce the launch of its newly designed website: www.therigy.com. The new design captures the look and spirit of Therigy’s brand and reflects the company’s position as the specialty pharmaceutical industry’s trusted source for technology, consulting, …